3-rx.comCustomer Support
3-rx.com
   
HomeAbout UsFAQContactHelp
News Center
Health Centers
Medical Encyclopedia
Drugs & Medications
Diseases & Conditions
Medical Symptoms
Med. Tests & Exams
Surgery & Procedures
Injuries & Wounds
Diet & Nutrition
Special Topics



\"$alt_text\"');"); } else { echo"\"$alt_text\""; } ?>


Join our Mailing List





Syndicate

You are here : 3-RX.com > Home > Drug News -

Statins do not appear to reduce the incidence of cancer

Drug NewsJan 06, 06

The cholesterol-lowering medications called statins do not appear to reduce the incidence of cancer or cancer deaths, according to a meta-analysis of previous studies in the January 4 issue of JAMA: The Journal of the American Medical Association.

Other studies have suggested that statins reduce the risk of developing cancer, the authors provide as background information in the review article. “Statins have been studied in numerous large-scale, randomized, active- or placebo-controlled trials for primary and secondary prevention of coronary artery disease. In these trials, statins reduced the risk of a first myocardial infarction (heart attack) and overall mortality. With long-term follow-up and collection of cancer data in a majority of studies, insight into the risk of cancer among statin-na? persons and statin users can be derived,” the authors write.

C. Michael White, Pharm.D., from the University of Connecticut and Hartford Hospital, Hartford, Conn., and colleagues, conducted a search of the medical literature from 1966 through July 2005 to identify randomized controlled trials of statins. They found 27 articles (n = 86,936 participants) that met their criteria for inclusion, reporting 26 randomized controlled trials of statins with data on either cancer incidence (n = 20 studies) or cancer death (n = 22 studies).

“In our current meta-analysis, statins did not reduce the incidence of cancer or cancer death,” the authors report. “No reductions were noted for cancers of the breast, colon, gastrointestinal tract, prostate, respiratory tract, or skin (melanoma) when statins were used.” The authors continue, “? the patients in our meta-analysis were primarily treated with simvastatin and pravastatin. As such, we evaluated pravastatin alone and simvastatin alone on cancer incidence and death and found no impact.”

“Statins have a neutral effect on cancer and cancer death risks in randomized controlled trials,” the authors write in conclusion. “We could find no type of cancer that statins benefited or subtype of statin that reduced the risk of cancer.

http://jama.ama-assn.org/



Print Version
Tell-a-Friend
comments powered by Disqus

RELATED ARTICLES:
  New biomarkers may influence drug design and alternative treatments of cancer, study shows
  UGA ecologist finds another cause of antibiotic resistance
  New drug for neuroblastoma shows promise in phase I study
  Baclofen shows promise in patients with alcohol-induced liver disease
  Findings point to an ‘off switch’ for drug resistance in cancer
  Stopping statins may benefit terminally ill patients
  Cholesterol drug users may use pills as a license to overeat
  Pfizer lung cancer drug beats chemo for previously untreated patients
  Mass. General study identifies path to safer drugs for heart disease, cancer
  Gates Foundation awards Notre Dame $23 million for malaria, dengue studies
  Cancer drug protects against diabetes
  Malaria drug target raises hopes for new treatments

 












Home | About Us | FAQ | Contact | Advertising Policy | Privacy Policy | Bookmark Site